| P2093 | author name string | Kenneth T Calamia | |
| | Phaedon G Kaklamanis | |
| P2860 | cites work | Human recombinant interferon alfa-2a for the treatment of Behçet's disease with sight threatening posterior or panuveitis | Q24671749 |
| | Autoinflammatory gene mutations in Behçet's disease | Q24674998 |
| | Anti-Saccharomyces cerevisiae antibodies in Behçet's disease--a familial study | Q28270517 |
| | Infliximab for the treatment of Neuro-Behçet's disease: a case series and review of the literature | Q31145072 |
| | Longterm visual prognosis of patients with ocular Adamantiades-Behçet's disease treated with interferon-alpha-2a. | Q33379273 |
| | Etanercept plus standard therapy for Wegener's granulomatosis | Q33984596 |
| | Short-term trial of etanercept in Behçet's disease: a double blind, placebo controlled study. | Q34381367 |
| | Whole-genome screening for susceptibility genes in multicase families with Behçet's disease | Q34423624 |
| | Erythema nodosum: clinicopathologic correlations and their use in differential diagnosis | Q34667744 |
| | Association of Major Histocompatibility Complex Class I Chain-Related Gene A and HLA-B Alleles with Behçet's Disease in Turkey | Q34730090 |
| | Treatment of ocular symptoms of Behçet's disease with interferon alpha 2a: a pilot study | Q35305133 |
| | The use of interferon alpha in Behçet disease: review of the literature | Q35744081 |
| | Intestinal perforations in Behçet's disease | Q35751523 |
| | Efficacy of interferon alpha in the treatment of refractory and sight threatening uveitis: a retrospective monocentric study of 45 patients | Q35763133 |
| | Behçet's disease as an autoinflammatory disorder | Q36048189 |
| | The spectrum of autoinflammatory diseases: recent bench to bedside observations | Q36048259 |
| | Neuro-Behçet's syndrome: differential diagnosis and management | Q36535240 |
| | Autoimmunity vs autoinflammation in Behcet's disease: do we oversimplify a complex disorder? | Q36602435 |
| | An update on Behçet's disease | Q36701009 |
| | Anti-TNF therapy in the management of Behcet's disease--review and basis for recommendations. | Q36778276 |
| | The role of infectious agents in the pathogenesis, clinical manifestations and treatment strategies in Behçet's disease. | Q36976055 |
| | MEFV mutations are increased in Behçet's disease (BD) and are associated with vascular involvement. | Q40542090 |
| | What does it take to diagnose Behçet disease? | Q46492284 |
| | CNS involvement occurs more frequently in patients with Behçet's disease under cyclosporin A (CSA) than under other medications--results of a retrospective analysis of 117 cases. | Q46784335 |
| | Differential efficacy of human recombinant interferon-alpha2a on ocular and extraocular manifestations of Behçet disease: results of an open 4-center trial | Q47778828 |
| | Evaluation of application of multiple needle pricks on the pathergy reaction | Q47805716 |
| | Anti-Saccharomyces cerevisiae antibody in intestinal Behçet's disease patients: relation to clinical course | Q48380639 |
| | Interferon-alpha--a new therapeutic option in refractory juvenile Behçet's disease with CNS involvement. | Q53215318 |
| | Linkage mapping of a novel susceptibility locus for Behçet's disease to chromosome 6p22-23 | Q57306883 |
| | Criteria for diagnosis of Behçet's disease. International Study Group for Behçet's Disease | Q68086434 |
| | Is there a place for large vessel disease in the diagnostic criteria of Behçet's disease? | Q73292526 |
| | Evidence for linkage of the HLA-B locus in Behçet's disease, obtained using the transmission disequilibrium test | Q73521709 |
| | Long-term clinical course and prognostic factors in intestinal Behçet's disease | Q73824402 |
| | Intravitreal triamcinolone acetonide in the management of cystoid macular edema in Behçet's disease | Q79566841 |
| | Can specific vessel-based papulopustular lesions of Behçet's disease be differentiated from nonspecific follicular-based lesions clinically? | Q79971935 |
| | Is anticoagulation unnecessary in Behcet's disease with deep venous thrombosis? | Q80163924 |
| | Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial | Q80242517 |
| | Long-term efficacy of infliximab in refractory posterior uveitis of Behcet's disease: a 24-month follow-up study | Q80263649 |
| | Treatment of venous thrombosis associated with Behcet's disease: immunosuppressive therapy alone versus immunosuppressive therapy plus anticoagulation | Q80629305 |
| | Results of intravitreal triamcinolone acetonide (IVTA) injection for the treatment of panuveitis attacks in patients with Behçet disease | Q81095139 |
| | Development of consensus statements for the diagnosis and management of intestinal Behçet's disease using a modified Delphi approach | Q81312227 |
| | Anti-TNF-alpha therapy in seven patients with Behcet's uveitis: advantages and controversial aspects | Q81386028 |
| | Histopathologic and direct immunofluorescence findings of the papulopustular lesions in Behçet's disease | Q83041416 |
| | Results of interferon-alfa therapy in patients with Behçet uveitis | Q83283962 |
| P433 | issue | 5 | |
| P921 | main subject | Behçet's disease | Q911427 |
| | diagnosis | Q16644043 |
| P304 | page(s) | 349-355 | |
| P577 | publication date | 2008-10-01 | |
| P1433 | published in | Current Rheumatology Reports | Q23930052 |
| P1476 | title | Behçet's disease: recent advances in early diagnosis and effective treatment | |
| P478 | volume | 10 | |